|
|
 |
 |
| |
 Printable version |
Salicylates: what’s new in 2008? |
Hépato-Gastro. Volume 15, Number 6, 464-9, Novembre-Décembre 2008, Mini-revue
|
 Résumé
Texte intégral
|
Author(s) : Mathurin Kowo, David Laharie |
Summary : Salicylates remain to this day the most prescribed drug for inflammatory bowel disease (IBD) patients, despite the availability of new therapies such as immunosuppressant and anti-TNFs. 4- and 5-aminosalicylate acids (4-ASA and 5-ASA) are the active components of this ancient therapeutic class. In the last few years, considerable progress has been made in understanding salicylates mode of action. Anti-inflammatory and antitumour effects of 5-ASA are mediated by peroxysome proliferator-activated receptor gamma (PPAR-γ). These data support numerous retrospective studies suggesting that salicylates reduce the risk of colorectal cancer among patients with IBD. New galenic forms of 5-ASA, coated with a novel multi-matrix delivery system to achieve a sustained release of the drug throughout the colon, are being developed. These new forms have an easy dosing schedule and may improve patient compliance. |
Keywords : aminosalicylates, IBD, Crohn’s disease, ulcerative colitis, colorectal cancer, chemoprevention |
|
